REFERENCES
1. Becher PM, Lund LH, Coats AJS, Savarese G. An update on global epidemiology in heart failure. Eur Heart J 2022;43:3005-7.
2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the american heart association. Circulation 2023;147:e93-621.
3. Li H, Hastings MH, Rhee J, Trager LE, Roh JD, Rosenzweig A. Targeting age-related pathways in heart failure. Circ Res 2020;126:533-51.
4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A-13A.
5. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-87.
6. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-56.
8. Uchmanowicz I, Gobbens RJ. The relationship between frailty, anxiety and depression, and health-related quality of life in elderly patients with heart failure. Clin Interv Aging 2015;10:1595-600.
9. Beltrami M, Fumagalli C, Milli M. Frailty, sarcopenia and cachexia in heart failure patients: different clinical entities of the same painting. World J Cardiol 2021;13:1-10.
10. Jeejeebhoy KN. Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. Curr Opin Clin Nutr Metab Care 2012;15:213-9.
11. Petermann-Rocha F, Pell JP, Celis-Morales C, Ho FK. Frailty, sarcopenia, cachexia and malnutrition as comorbid conditions and their associations with mortality: a prospective study from UK biobank. J Public Health 2022;44:e172-80.
12. Mirzai S, Eck BL, Chen PH, Estep JD, Tang WHW. Current approach to the diagnosis of sarcopenia in heart failure: a narrative review on the role of clinical and imaging assessments. Circ Heart Fail 2022;15:e009322.
13. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
14. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010;29:154-9.
15. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology 2014;60:294-305.
16. Wang DXM, Yao J, Zirek Y, Reijnierse EM, Maier AB. Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis. J Cachexia Sarcopenia Muscle 2020;11:3-25.
17. Yeung SSY, Reijnierse EM, Pham VK, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2019;10:485-500.
18. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One 2017;12:e0169548.
19. Xu J, Wan CS, Ktoris K, Reijnierse EM, Maier AB. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology 2022;68:361-76.
20. Chen R, Xu J, Wang Y, et al. Prevalence of sarcopenia and its association with clinical outcomes in heart failure: an updated meta-analysis and systematic review. Clin Cardiol 2023;46:260-8.
21. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2013;34:512-9.
22. Yuan S, Larsson SC. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism 2023;144:155533.
23. Machackova J, Barta J, Dhalla NS. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol 2006;22:953-68.
24. Kostin S, Pool L, Elsässer A, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003;92:715-24.
25. Narumi T, Watanabe T, Kadowaki S, et al. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. Eur J Intern Med 2015;26:118-22.
26. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3.
27. Konishi M, Kagiyama N, Kamiya K, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Eur J Prev Cardiol 2021;28:1022-9.
28. Landi F, Marzetti E, Martone AM, Bernabei R, Onder G. Exercise as a remedy for sarcopenia. Curr Opin Clin Nutr Metab Care 2014;17:25-31.
29. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc: “hic et nunc” - here and now. Int J Cardiol 2015;201:e1-12.
30. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
31. Del Buono MG, Arena R, Borlaug BA, et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2209-25.
32. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol 2017;14:323-41.
33. Piepoli MF, Davos C, Francis DP, Coats AJ. ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
34. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
35. Yamamoto E, Kato T, Yaku H, et al. Appetite loss at discharge from acute decompensated heart failure: observation from KCHF registry. PLoS One 2022;17:e0267327.
36. The 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American geriatrics society 2019 updated AGS beers criteria® for Potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;67:674-94.
37. Rocha de Avila Pelozin B, Felipe Rodrigues L, Menezes De Oliveira E, Fernandes T. Cardiac and cancer-associated cachexia: role of exercise training, non-coding RNAs, and future perspectives. In: D’Onofrio G, Cseri J, editors. Frailty and sarcopenia - recent evidence and new perspectives. IntechOpen; 2022.
38. Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer cachexia: beyond weight loss. J Oncol Pract 2016;12:1163-71.
39. Musolino V, Palus S, Tschirner A, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle 2016;7:555-66.
40. Fernández-Pombo A, Rodríguez-Carnero G, Castro AI, et al. Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure. Clin Nutr 2021;40:5141-55.
41. Habaybeh D, de Moraes MB, Slee A, Avgerinou C. Nutritional interventions for heart failure patients who are malnourished or at risk of malnutrition or cachexia: a systematic review and meta-analysis. Heart Fail Rev 2021;26:1103-18.
42. Maimónides Biomedical Research Institute of Córdoba. Mediterranean diet and nutritional support in heart failure sarcopenia. 2023. Available from: https://clinicaltrials.gov/study/NCT05848960 [Last accessed on 21 Dec 2023].
43. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102:488-96.
44. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93:425-34.
45. Lee JY, Kim DA, Choi E, Lee YS, Park SJ, Kim BJ. Aldosterone inhibits in vitro myogenesis by increasing intracellular oxidative stress via mineralocorticoid receptor. Endocrinol Metab 2021;36:865-74.
46. Burton LA, McMurdo MET, Struthers AD. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? Clin Endocrinol 2011;75:725-9.
47. Angelidis G, Valotassiou V, Georgoulias P. Current and potential roles of ghrelin in clinical practice. J Endocrinol Invest 2010;33:823-38.
48. Akamizu T, Kangawa K. Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect. Peptides 2011;32:2295-300.
49. Xin X, Ren AJ, Zheng X, et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides 2009;30:2281-5.
50. Lenk K, Palus S, Schur R, et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle 2013;4:63-9.
51. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
52. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004;110:3674-9.
53. Zhang G, Yin X, Qi Y, et al. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010;6:62-70.
55. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
56. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-7.
57. Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, Gharipour M. Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. Biomed Res Int 2014;2014:392432.
58. Dos Santos MR, Sayegh ALC, Bacurau AVN, et al. Effect of exercise training and testosterone replacement on skeletal muscle wasting in patients with heart failure with testosterone deficiency. Mayo Clin Proc 2016;91:575-86.
59. Stout M, Tew GA, Doll H, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J 2012;164:893-901.
60. Navarro-Peñalver M, Perez-Martinez MT, Gómez-Bueno M, et al. Testosterone replacement therapy in deficient patients with chronic heart failure: a randomized double-blind controlled pilot study. J Cardiovasc Pharmacol Ther 2018;23:543-50.
61. Malkin CJ, Pugh PJ, West JN, van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
62. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107-17.
63. Sculthorpe N, Solomon AM, Sinanan ACM, Bouloux PMG, Grace F, Lewis MP. Androgens affect myogenesis in vitro and increase local IGF-1 expression. Med Sci Sports Exerc 2012;44:610-5.
64. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998;275:E864-71.
65. Powers ML, Florini JR. A direct effect of testosterone on muscle cells in tissue culture. Endocrinology 1975;97:1043-7.
66. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017;168:960-76.
67. Adhikari R, Jha K, Dardari Z, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc 2022;11:e023811.
68. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the american college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022;79:1757-80.
69. Massimino E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells 2021;10:1958.
70. Dyck JRB, Sossalla S, Hamdani N, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol 2022;167:17-31.
71. Takada S, Sabe H, Kinugawa S. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies. Am J Physiol Heart Circ Physiol 2022;322:H117-28.
72. Rutledge C, Enriquez A, Redding K, et al. Liraglutide protects against diastolic dysfunction and improves ventricular protein translation. Cardiovasc Drugs Ther 2023.
73. Moore PW, Malone K, VanValkenburg D, et al. GLP-1 agonists for weight loss: pharmacology and clinical implications. Adv Ther 2023;40:723-42.
74. Wang JY, Wang QW, Yang XY, et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol 2023;14:1085799.
75. Gurjar AA, Kushwaha S, Chattopadhyay S, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism 2020;103:154044.
76. Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle 2019;10:903-18.
77. Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. Nat Metab 2023;5:546-62.
78. Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest 2018;128:3716-26.
79. Lai L, Leone TC, Keller MP, et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 2014;7:1022-31.
80. Sagar S, Gustafsson AB. Cardiovascular aging: the mitochondrial influence. J Cardiovasc Aging 2023;3:33.
81. Mishra P, Varuzhanyan G, Pham AH, Chan DC. Mitochondrial dynamics is a distinguishing feature of skeletal muscle fiber types and regulates organellar compartmentalization. Cell Metab 2015;22:1033-44.
82. Adhihetty PJ, O'Leary MFN, Chabi B, Wicks KL, Hood DA. Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle. J Appl Physiol 2007;102:1143-51.
83. Romanello V, Guadagnin E, Gomes L, et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J 2010;29:1774-85.
84. Coen PM, Musci RV, Hinkley JM, Miller BF. Mitochondria as a target for mitigating sarcopenia. Front Physiol 2019;9:01883.
85. Mau T, Blackwell TL, Cawthon PM, et al. Muscle mitochondrial bioenergetic capacities is associated with multimorbidity burden in older adults: the study of muscle, mobility and aging (SOMMA). 2023. Available from: https://www.x-mol.net/paper/detail/1721994890604990464 [Last accessed on 21 Dec 2023].
86. Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH, Powers SK. Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. J Appl Physiol 2011;111:1459-66.
87. McDonagh B, Scullion SM, Vasilaki A, Pollock N, McArdle A, Jackson MJ. Ageing-induced changes in the redox status of peripheral motor nerves imply an effect on redox signalling rather than oxidative damage. Free Radic Biol Med 2016;94:27-35.
88. Lv J, Li Y, Shi S, et al. Skeletal muscle mitochondrial remodeling in heart failure: an update on mechanisms and therapeutic opportunities. Biomed Pharmacother 2022;155:113833.
91. van der Ent M, Jeneson JA, Remme WJ, Berger R, Ciampricotti R, Visser F. A non-invasive selective assessment of type I fibre mitochondrial function using 31PNMR spectroscopy: evidence for impaired oxidative phosphorylation rate in skeletal muscle in patients with chronic heart failure. Eur Heart J 1998;19:124-31.
92. Doenst T, Pytel G, Schrepper A, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 2010;86:461-70.
93. Knapp F, Niemann B, Li L, et al. Differential effects of right and left heart failure on skeletal muscle in rats. J Cachexia Sarcopenia Muscle 2020;11:1830-49.
94. Schrepper A, Schwarzer M, Schöpe M, Amorim PA, Doenst T. Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload - role of respiratory chain complex activity. J Mol Cell Cardiol 2012;52:125-35.
95. Acin-Perez R, Benincá C, Shabane B, Shirihai OS, Stiles L. Utilization of human samples for assessment of mitochondrial bioenergetics: gold standards, limitations, and future perspectives. Life 2021;11:949.
96. Guzmán Mentesana G, Báez AL, Lo Presti MS, et al. Functional and structural alterations of cardiac and skeletal muscle mitochondria in heart failure patients. Arch Med Res 2014;45:237-46.
97. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res 2014;114:524-37.
98. Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Compr Physiol 2011;1:941-69.
99. Jang JY, Blum A, Liu J, Finkel T. The role of mitochondria in aging. J Clin Invest 2018;128:3662-70.
100. Pinti M, Cevenini E, Nasi M, et al. Circulating mitochondrial DNA increases with age and is a familiar trait: implications for “inflamm-aging”. Eur J Immunol 2014;44:1552-62.
101. Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014;54:289-96.
102. West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 2017;17:363-75.
103. Shadel GS, Clayton DA. Mitochondrial DNA maintenance in vertebrates. Annu Rev Biochem 1997;66:409-35.
104. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-35.
105. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res 2010;106:1541-8.
106. Hiona A, Leeuwenburgh C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol 2008;43:24-33.
107. Mettauer B, Zoll J, Garnier A, Ventura-Clapier R. Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch 2006;452:653-66.
108. Bețiu AM, Noveanu L, Hâncu IM, et al. Mitochondrial effects of common cardiovascular medications: the good, the bad and the mixed. Int J Mol Sci 2022;23:13653.
109. Zoll J, Monassier L, Garnier A, et al. ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. J Appl Physiol 2006;101:385-91.
110. Bacurau AV, Cunha TF, Souza RW, Voltarelli VA, Gabriel-Costa D, Brum PC. Aerobic exercise and pharmacological therapies for skeletal myopathy in heart failure: similarities and differences. Oxid Med Cell Longev 2016;2016:4374671.
111. Casuso RA, Huertas JR. The emerging role of skeletal muscle mitochondrial dynamics in exercise and ageing. Ageing Res Rev 2020;58:101025.
112. Niemann B, Chen Y, Issa H, Silber RE, Rohrbach S. Caloric restriction delays cardiac ageing in rats: role of mitochondria. Cardiovasc Res 2010;88:267-76.
113. No MH, Heo JW, Yoo SZ, et al. Effects of aging and exercise training on mitochondrial function and apoptosis in the rat heart. Pflugers Arch 2020;472:179-93.
114. Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med 2019;51:1-13.
115. Ussher JR, Jaswal JS, Lopaschuk GD. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 2012;111:628-41.
116. Walker MA, Tian R. Raising NAD in heart failure: time to translate? Circulation 2018;137:2274-7.
117. Prolla TA, Denu JM. NAD+ deficiency in age-related mitochondrial dysfunction. Cell Metab 2014;19:178-80.
118. Henning RH, Brundel BJJM. Proteostasis in cardiac health and disease. Nat Rev Cardiol 2017;14:637-53.
119. Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 2019;20:421-35.
120. Hetz C, Chevet E, Oakes SA. Proteostasis control by the unfolded protein response. Nat Cell Biol 2015;17:829-38.
121. Rutledge CA, Lagranha C, Chiba T, et al. Metformin preconditioning protects against myocardial stunning and preserves protein translation in a mouse model of cardiac arrest. J Mol Cell Cardiol Plus 2023;4:100034.
122. Meijering RAM, Zhang D, Hoogstra-Berends F, Henning RH, Brundel BJJM. Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins. Front Physiol 2012;3:36. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2012.00036 [Last accessed on 21 Dec 2023].
123. Christians ES, Benjamin IJ. Proteostasis and REDOX state in the heart. Am J Physiol Heart Circ Physiol 2012;302:H24-37.
124. Mainali N, Ayyadevara S, Ganne A, Shmookler Reis RJ, Mehta JL. Protein homeostasis in the aged and diseased heart. J Cardiovasc Aging 2023;3:16.
125. Paez HG, Pitzer CR, Alway SE. Age-related dysfunction in proteostasis and cellular quality control in the development of sarcopenia. Cells 2023;12:249.
126. Wu M, Falasca M, Blough ER. Akt/protein kinase B in skeletal muscle physiology and pathology. J Cell Physiol 2011;226:29-36.
127. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol 2023;24:255-72.
128. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696-705.
129. Bujak AL, Crane JD, Lally JS, et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab 2015;21:883-90.
130. O’Neill HM. AMPK and exercise: glucose uptake and insulin sensitivity. Diabetes Metab J 2013;37:1-21.
131. Cao Y, Bojjireddy N, Kim M, et al. Activation of γ2-AMPK suppresses ribosome biogenesis and protects against myocardial ischemia/reperfusion injury. Circ Res 2017;121:1182-91.
132. Sorrenti V, Benedetti F, Buriani A, et al. Immunomodulatory and antiaging mechanisms of resveratrol, rapamycin, and metformin: focus on mTOR and AMPK signaling networks. Pharmaceuticals 2022;15:912.
133. Ziaaldini MM, Marzetti E, Picca A, Murlasits Z. Biochemical pathways of sarcopenia and their modulation by physical exercise: a narrative review. Front Med 2017;4:167.
134. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
135. Basualto-Alarcón C, Jorquera G, Altamirano F, Jaimovich E, Estrada M. Testosterone signals through mTOR and androgen receptor to induce muscle hypertrophy. Med Sci Sports Exerc 2013;45:1712-20.
136. Cabello-Verrugio C, Cordova G, Salas JD. Angiotensin II: role in skeletal muscle atrophy. Curr Protein Pept Sci 2012;13:560-9.
137. Bossola M, Pacelli F, Costelli P, Tortorelli A, Rosa F, Doglietto GB. Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology 2008;9:261-8.
138. Whitman SA, Wacker MJ, Richmond SR, Godard MP. Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age. Pflugers Arch 2005;450:437-46.
139. Centner T, Yano J, Kimura E, et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 2001;306:717-26.
140. Chen SN, Czernuszewicz G, Tan Y, et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 2012;111:907-19.
141. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
142. Altun M, Besche HC, Overkleeft HS, et al. Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem 2010;285:39597-608.
143. Maejima Y, Usui S, Zhai P, et al. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A. Circ Heart Fail 2014;7:479-90.
144. Patterson C, Willis MS, Portbury A. Rise above: muscle ring-finger-1 (MURF1) regulation of cardiomyocyte size and energy metabolism. Trans Am Clin Climatol Assoc 2011;122:70-81.
145. Willis MS, Schisler JC, Li L, et al. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 2009;105:80-8.
146. Mangner N, Weikert B, Bowen TS, et al. Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm. J Cachexia Sarcopenia Muscle 2015;6:381-90.
147. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012;125:2716-27.
148. Souza RWA, Piedade WP, Soares LC, et al. Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions. PLoS One 2014;9:e110020.
149. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-5.
150. Dehoux MJM, van Beneden RP, Fernández-Celemín L, Lause PL, Thissen JPM. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 2003;544:214-7.
151. Adams V, Linke A, Wisloff U, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res 2007;73:120-9.
152. Razeghi P, Baskin KK, Sharma S, et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun 2006;342:361-4.
153. Carvalho RF, Castan EP, Coelho CA, et al. Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy. J Mol Histol 2010;41:81-7.
154. Santoyo-Suarez MG, Mares-Montemayor JD, Padilla-Rivas GR, et al. The involvement of krüppel-like factors in cardiovascular diseases. Life 2023;13:420.
155. Xu M, Chen X, Chen D, Yu B, Huang Z. FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification. Oncotarget 2017;8:10662-74.
156. Hirata Y, Nomura K, Kato D, et al. A piezo1/KLF15/IL-6 axis mediates immobilization-induced muscle atrophy. J Clin Invest 2022;132:1-13.
157. Gan Z, Fu T, Kelly DP, Vega RB. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res 2018;28:969-80.
158. Prosdocimo DA, Sabeh MK, Jain MK. Kruppel-like factors in muscle health and disease. Trends Cardiovasc Med 2015;25:278-87.
159. Pollak NM, Hoffman M, Goldberg IJ, Drosatos K. Krüppel-like factors: crippling and un-crippling metabolic pathways. JACC Basic Transl Sci 2018;3:132-56.
160. Sweet DR, Fan L, Hsieh PN, Jain MK. Krüppel-like factors in vascular inflammation: mechanistic insights and therapeutic potential. Front Cardiovasc Med 2018;5:6.
161. He C, Sumpter R Jr, Levine B. Exercise induces autophagy in peripheral tissues and in the brain. Autophagy 2012;8:1548-51.
162. Grumati P, Coletto L, Schiavinato A, et al. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy 2011;7:1415-23.
163. Sanchez AMJ, Csibi A, Raibon A, et al. AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1. J Cell Biochem 2012;113:695-710.
164. Grumati P, Coletto L, Sabatelli P, et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med 2010;16:1313-20.
165. Fujita N, Fujino H, Sakamoto H, Takegaki J, Deie M. Time course of ubiquitin-proteasome and macroautophagy-lysosome pathways in skeletal muscle in rats with heart failure. Biomed Res 2015;36:383-92.
166. Jannig PR, Moreira JBN, Bechara LRG, et al. Autophagy signaling in skeletal muscle of infarcted rats. PLoS One 2014;9:e85820.
167. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999;33:959-65.
169. Xie G, Jin H, Mikhail H, et al. Autophagy in sarcopenia: possible mechanisms and novel therapies. Biomed Pharmacother 2023;165:115147.
170. Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol 2002;85:33-49.
171. Krysztofiak H, Wleklik M, Migaj J, et al. Cardiac cachexia: a well-known but challenging complication of heart failure. Clin Interv Aging 2020;15:2041-51.
172. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
173. Clark DJ, Cleman MW, Pfau SE, et al. Serum complement activation in congestive heart failure. Am Heart J 2001;141:684-90.
174. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
175. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8.
177. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-91.
178. Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000;102:1690-6.
179. Schaap LA, Pluijm SMF, Deeg DJH, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009;64:1183-9.
180. Dirks AJ, Leeuwenburgh C. Tumor necrosis factor alpha signaling in skeletal muscle: effects of age and caloric restriction. J Nutr Biochem 2006;17:501-8.
181. Costelli P, Carbó N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993;92:2783-9.
182. Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998;98:794-9.
183. Suematsu N, Tsutsui H, Wen J, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003;107:1418-23.
184. Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-43.
185. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71.
186. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
187. Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun 2021;12:330.
188. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
189. Tsujinaka T, Ebisui C, Fujita J, et al. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun 1995;207:168-74.
190. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-93.
191. Martins T, Vitorino R, Moreira-Gonçalves D, Amado F, Duarte JA, Ferreira R. Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. Clin Biochem 2014;47:8-15.
192. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. Annu Rev Physiol 2010;72:81-94.
193. Moylan JS, Smith JD, Chambers MA, McLoughlin TJ, Reid MB. TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am J Physiol Cell Physiol 2008;295:C986-93.
194. Rodríguez-Nuevo A, Zorzano A. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress 2019;3:195-207.
195. Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: the rising star in cardiovascular diseases. Front Cardiovasc Med 2022;9:927061.
196. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJS. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426-30.
197. Liu CF, Tang WHW. Gut microbiota in sarcopenia and heart failure. J Cardiovasc Aging 2022;2:35.
198. Ferrari R, Bachetti T, Agnoletti L, Comini L, Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J 1998;19 Suppl G:G41-7.
199. Dos Santos MR, Saitoh M, Ebner N, et al. Sarcopenia and endothelial function in patients with chronic heart failure: results from the studies investigating comorbidities aggravating heart failure (SICA-HF). J Am Med Dir Assoc 2017;18:240-5.
200. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 1984;69:1079-87.
201. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803-15.
202. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
203. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
